Collaboration UMC Utrecht for Bone Regeneration Therapy

NecstGen and UMC Utrecht partner to advance bone regeneration therapy using MSC-derived spheroids, marking a significant step in regenerative medicine.

Leiden, Netherlands — NecstGen, the Netherlands Center for the Clinical Advancement of Stem Cell and Gene Therapies, is proud to announce a collaboration with Dr. Debby Gawlitta of the Department of Oral and Maxillofacial Surgery & Special Dental Care at UMC Utrecht. This collaboration aims to develop a pioneering therapy for bone defects, leveraging the power of mesenchymal stromal cell (MSC)-derived spheroids.

Dr. Gawlitta’s research has demonstrated promising results in preclinical studies, showcasing successful endochondral bone regeneration in rat and goat models. These findings show the potential of devitalised bone marrow-derived MSC-spheroids in treating bone defects, a significant advancement in regenerative medicine.

Through this collaboration, NecstGen will support Dr. Gawlitta’s project by offering development support of this innovative therapy.

“We are excited about the potential of this collaboration with Dr. Gawlitta,” said Paul Bilars, CEO of NecstGen. “Our mission is to accelerate the delivery of innovative medicinal products to patients. This project exemplifies our commitment to support the next generation of therapies that can significantly impact patients’ lives.”

The project focuses on the GMP manufacturing of human MSC-derived spheroids, targeting maxillofacial and spinal fusion defects. It encompasses an extensive process, including expanding MSCs, spheroid formation, and rigorous quality control assays to ensure the required safety and efficacy standards.

This collaboration marks a significant step forward in bone regeneration therapy and reinforces the importance of partnerships between academia and industry in advancing healthcare innovations.

Dr. Gawlitta has received a RegMed XB/Dutch Cardiovascular Alliance Thematic Tech Transfer Voucher sponsoring this collaborative activity to further develop her innovative findings into treatments. “This subsidy of RegMed XB/DCA for propelling advanced therapies to clinical implementation is coming at the right time to explore and take our next steps in the translational axis. The expertise and experience of NecstGen in this field is instrumental in designing our envisaged bone regenerative treatments.”

For more information about NecstGen, please visit necstgen.com.

About NecstGen

NecstGen is a non-profit CDMO and centre of excellence for Cell and Gene Therapy, located in a purpose-built GMP facility on the largest bio-cluster in the Netherlands, Leiden Bio Science Park. NecstGen provides critical contract development, manufacturing and rental services to academic and industrial therapy developers to deliver a new generation of therapies to patients.

About RegMed XB/Dutch CardioVascular Alliance TTT Voucher

The Thematic Tech Transfer (TTT) vouchers from RegMed XB/Dutch CardioVascular Alliance support the valorization trajectory of promising academic research within the regenerative and/or cardiovascular medicine fields. For more information, please visit www.tttransfer.nl and contact our impact officers.

EIC Awards €2.5 Million Grant

EIC Awards €2.5 Million Grant

Following a rigorous selection process by an expert panel, Trince, NecstGen, and IBSAL are proud to announce that their “Penphomet” project has been selected by The European Innovation Council (EIC) for a significant grant of €2.5 million.

Cell Therapy Manufacturing & Development

Viral Vector Manufacturing & Development

Cleanroom Rental